Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Platelet Inhibitor Therapy
Tailored Use May Prevent Second Heart Attacks
March 31st, 2000
Researchers at Duke University Medical Center think they know why glycoprotein IIb/IIIa platelet inhibitor drugs, collectively known as "super aspirins," produce only modest benefit for patients with acute coronary syndromes: they are often being used on patients who gain very little benefit. In the process of tabulating results on a trial of lamifiban, one of three intravenous super aspirins that have been tested, the researchers discovered that a simple blood test identified patients who benefited markedly when the drug was used. In those patients, improvement in the risk of death and a second heart attack was about 50%, compared to patients who received a...
Source: Drug Week (2000-03-31)
|
